Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study
Cataldo Patruno, Gabriella Fabbrocini, G. Longo, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 581-586
Closed Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Expert consensus on the systemic treatment of atopic dermatitis in special populations
David N. Adam, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 6, pp. 1135-1148
Open Access | Times Cited: 50
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 49
Clinical phenotypes of adult atopic dermatitis and related therapies
Cataldo Patruno, Luca Potestio, Maddalena Napolitano
Current Opinion in Allergy and Clinical Immunology (2022) Vol. 22, Iss. 4, pp. 242-249
Closed Access | Times Cited: 51
Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study
Maddalena Napolitano, Gabriella Fabbrocini, Iria Neri, et al.
Pediatric Drugs (2022) Vol. 24, Iss. 6, pp. 671-678
Open Access | Times Cited: 48
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
Maddalena Napolitano, Francesca di Vico, Angelo Ruggiero, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 26
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 953-961
Open Access | Times Cited: 25
Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis
Xiyuan Zhou, Ge Yang, Xuemei Zeng, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 12
A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
Masahiro Kamata, Yayoi Tada
JID Innovations (2021) Vol. 1, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 56
Dupilumab for the treatment of adult atopic dermatitis in special populations
Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 7, pp. 3028-3033
Closed Access | Times Cited: 33
A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis
Maddalena Napolitano, Gabriella Fabbrocini, Luca Potestio, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Closed Access | Times Cited: 30
Atopic dermatitis: treatment and innovations in immunotherapy
Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 3, pp. 1777-1789
Closed Access | Times Cited: 7
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
Marco Miniotti, Giulia Lazzarin, Michela Ortoncelli, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 5
Open Access | Times Cited: 28
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F. Murrell, P. Joly, Victoria P. Werth, et al.
Advances in Therapy (2024) Vol. 41, Iss. 7, pp. 2991-3002
Open Access | Times Cited: 5
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
Jonathan I. Silverberg, Charles Lynde, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 3, pp. 469-483
Open Access | Times Cited: 12
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
Cataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China
Yuyi Wang, Ruiling Jia, Hu Qin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
The Global Burden of Atopic Dermatitis in Elderly Populations: Trends, Disparities, and Future Projections
Zizhuo Li, Jieruo Gu, Tian Tang, et al.
Healthcare (2025) Vol. 13, Iss. 7, pp. 788-788
Open Access
Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks
Luca Mastorino, Vania L. CANTAFIO DUÒ, Cristina VECCO, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 12
Closed Access | Times Cited: 15
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Marina Calabrese, Martina D’Onghia, Laura Lazzeri, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 775-775
Open Access | Times Cited: 3
Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System
Austin R. Swisher, Rijul S. Kshirsagar, Nithin D. Adappa, et al.
The Laryngoscope (2021) Vol. 132, Iss. 12, pp. 2307-2313
Closed Access | Times Cited: 19
Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
Thomas A. Luger, William Romero, David Gruben, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 4, pp. 949-969
Open Access | Times Cited: 14
Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
Bingjing Zhou, Cong Peng, Liqiao Li, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Innovative Immunotherapy for the Treatment of Atopic Dermatitis: Focus on the European and Latin American Regulatory Frameworks
Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo, et al.
Current Dermatology Reports (2024) Vol. 13, Iss. 2, pp. 55-66
Closed Access | Times Cited: 2
Long-term Remission of Severe and Refractory Chronic Actinic Dermatosis with Dupilumab: A Case Report with Review of the Literature
C. Vanhaecke, M. Viguier
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40453-adv40453
Open Access | Times Cited: 2
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024
Michael R. Ardern‐Jones, Sara Brown, Carsten Flohr, et al.
British Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top